VolitionRx Limited (NYSE American: VNRX) is drawing attention to an expanding body of clinical and scientific evidence supporting its Nu.Q NETs assay as a biomarker for sepsis and other diseases associated with NETosis. The company released an educational video featuring Critical Care Lead and Medical Consultant Dr. Andrew Retter, underscoring the potential of the Nu.Q H3.1 test to improve patient management.
Multiple studies have demonstrated that Volition's Nu.Q H3.1 test can distinguish sepsis from non-infectious inflammation, correlate with disease severity, and provide strong prognostic value for outcomes including organ failure and mortality. According to the company, most of this research has been peer reviewed and published, with experts noting consistency across multiple countries and patient populations.
Volition believes its low-cost nucleosome quantification technology could help personalize patient care by identifying elevated H3.1 nucleosome levels as a treatable trait in sepsis management and informing future therapeutic strategies. The company is focused on advancing the science of epigenetics through simple, easy-to-use, cost-effective blood tests for early detection and monitoring of diseases like cancer and sepsis.
For more details, the full press release is available at https://ibn.fm/2IH3m.
Volition is a multinational company dedicated to saving lives and improving outcomes for people and animals with life-altering diseases. Its research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London. Further information can be found on the company's website at https://volition.com/.
This announcement highlights the growing importance of Nu.Q NETs in clinical settings, potentially offering a new tool for early sepsis detection and personalized treatment.
